MoonLake announces significant improvements with Nanobody&#x

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at...

Related Keywords

United States , Switzerland , San Diego , California , Americans , American , Kristian Reich , Kennethb Gordon , Ashley Tapp , Hidradenitis Suppurativa , Mary Jane Elliott , Matthias Bodenstedt , Moonlake Immunotherapeutics , Namrata Taak , Joseph Merola , Patricia Sousa , Josephf Merola , American Academy Of Dermatology , International Hidradenitis Suppurativa Severity Score System , Company Rd Day , Hotel Westin Bayview , Drug Administration , Health Assessment Questionnaire , Eu European Medicines Agency , College Of Wisconsin , Exchange Commission , American College Of Rheumatology , Nasdaq , Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium , Ut Southwestern Medical Center , Komodo Health Inc , Minimal Disease Activity , American Academy , American College , Psoriasis Area Severity Index , Chief Scientific Officer , Founding President , Medicines Agency , Medical College , Chief Executive Officer , Medical Center , Professor Kenneth , Professor Brian Kirby , Psoriasis Area , Severity Index , Health Assessment Questionnaire Disability Index , Leeds Enthesitis Index , Patients Assessment , Hidradenitis Suppurativa Clinical Response , Dermatology Life Quality Index , Numerical Rating Scale , Global Assessment , Skin Pain , Global Assessment Score , Securities Litigation Reform Act , Annual Report , Jane Elliott , Nasdaq Mltx , Moonlake Immunotherapeutics Ag , Moonlake , Jorge Santos Da Silva , Onelokimab , Psoriatic Arthritis , Idradenitis Supparativa ,